drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
A human monoclonal antibody targeting HBsAg that neutralizes HBV virions/subviral particles and, via Fc engineering, enhances Fcγ receptor–mediated effector functions (ADCC/ADCP) to promote clearance of HBsAg-expressing hepatocytes.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Monoclonal
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Human monoclonal antibody to HBsAg that neutralizes circulating HBV virions and subviral particles and, via Fc engineering, enhances Fc gamma receptor–mediated effector functions (ADCC/ADCP) to promote clearance of HBsAg-expressing hepatocytes and reduce HBsAg levels.
drug_name
VIR-3434 (tobevibart)
nct_id_drug_ref
NCT05612581